IDEAYA Biosciences Has Selected Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-small Cell Lung Cancer, Based On The Adverse Event Profile And Preliminary Clinical Efficacy
IDEAYA Biosciences Has Selected Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-small Cell Lung Cancer, Based On The Adverse Event Profile And Preliminary Clinical Efficacy
IDEAYA Biosciences 根据不良事件概况和初步临床疗效，为 MTAP 缺失鳞状非小细胞肺癌的 IDE397 单一疗法选择了向前推进的 2 期扩张剂量
- Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1
- Evaluating over 40 MTAP PDX preclinical models, squamous NSCLC was identified as the most sensitive tumor type to IDE397 monotherapy where ~50% of the models observed tumor regressions at 30mg/kg QD
- Over 100,000 global annual incidence of MTAP-deletion squamous NSCLC
- 根据 AE 概况和观察到的初步临床疗效，包括 RECIST 1.1 的多项部分反应，选择了针对 mTAP 缺失鳞状非小细胞肺癌的 IDE397 单一疗法的 2 期扩张剂量
- 通过评估 40 多个 MTAP PDX 临床前模型，鳞状非小细胞肺癌被确定为对 IDE397 单一疗法最敏感的肿瘤类型，其中约 50% 的模型在 30mg/kg QD 时观察到肿瘤回归
- MTAP 缺失鳞状非小细胞肺癌的全球年发病率超过 100,000
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。